> FETCHING JOB RECORD
skill:oracle-assess
Answer this question about chain 1 over blocks 26057653 to 26057952 (closing hash 0x9eed4463399fbfc0e13ce629737f560e4b8202b2957705e48c48fa2556cf9c1b), exactly…
VERDICT: paths and tree verified; no suite was run for this kind of work
Done. The checker prints `ok` for `artifacts/answer.json`. **Answer:** ADARx Pharmaceuticals (Nasdaq: ADRX) priced its upsized IPO at **$17.00 per share** on September 24, 2026 — the top of its $15–$17 range. The offering was upsized to 26,250,000 shares for roughly $446.3 million in gross proceeds, with AbbVie's concurrent private placement also struck at $17.00. Whole-dollar `uint256` answer: `17`. Deliverable is a `panel` recipe naming the issuer's September 24, 2026 pricing announcement as the source, corroborated by Investing.com's report of the same figure. The pinned window and closing hash are copied exactly from the brief, and the file is untracked. Sources: - [ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering | Valuespectrum.com](https://www.valuespectrum.com/corporate_news/1495979-adarx-pharmaceuticals-announces-pricing-of-upsized-446-3-million-initial-public-offering) - [ADARx Pharmaceuticals prices $446.3M IPO at $17 per share By Investing.com](https://in.investing.com/news/stock-market-news/adarx-pharmaceuticals-prices-4463m-ipo-at-17-per-share-432SI-5605868)
Created [artifacts/answer.json](/home/seat/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json) with answer `17`, citing ADARx’s GlobeNewswire announcement syndicated by Yahoo Finance. Validation passed: `ok`.
Completed and verified. - Answer: `$17` per share - Output: [artifacts/answer.json](/home/imd-worker/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json) - Checker result: `ok`
Created [artifacts/answer.json](/home/seat/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json) with answer `17`, sourced to ADARx’s investor-relations release. Validation passed: `ok`.
Created [artifacts/answer.json](/home/imd-worker/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json) with the answer **$17 per share**, based on ADARx’s [press release syndicated by Yahoo Finance](https://finance.yahoo.com/news/adarx-pharmaceuticals-announces-pricing-upsized-233300857.html). The required checker passed: `ok`.
Created [artifacts/answer.json](/home/seat/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json) with answer `17`, sourced to Yahoo Finance’s published announcement. Validation passed: `ok`.
ADARx priced the upsized IPO at **$17 per share**. Its [September 24 company announcement](https://investors.adarx.com/news-releases/news-release-details/adarx-pharmaceuticals-announces-pricing-upsized-4463-million) states $17.00 per share. Wrote [artifacts/answer.json](/home/debian/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json). The required checker printed `ok`.
Answered **$17 per share** in [artifacts/answer.json](/home/imd/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json), citing ADARx’s GlobeNewswire release. The checker prints `ok`.
Created [artifacts/answer.json](/home/seat/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json) with answer `17`, citing the GlobeNewswire release syndicated by Yahoo Finance. Validation passed: `ok`.
Checker passes. ADARx priced its upsized IPO at $17.00/share (26,250,000 shares, ~$446.3M gross), per the ADARx/GlobeNewswire press release republished by BioSpace, corroborated by IPOScoop and Bloomberg. `artifacts/answer.json` is written with answer "17" and recipe kind "panel" citing these sources.
Wrote [artifacts/answer.json](/home/seat12/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json) with the answer **$17 per share**, as reported in ADARx’s [September 24 press release](https://www.globenewswire.com/news-release/2026/09/24/3368818/0/en/adarx-pharmaceuticals-announces-pricing-of-upsized-446-3-million-initial-public-offering.html). The supplied checker prints `ok`.
ADARx priced the upsized IPO at **$17 per share**, as stated in its [September 24 press release](https://investors.adarx.com/news-releases/news-release-details/adarx-pharmaceuticals-announces-pricing-upsized-4463-million). Created [artifacts/answer.json](/root/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json). The provided checker prints `ok`.
The answer is **$17 per share**. I wrote [artifacts/answer.json](/home/worker/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json) with the GlobeNewswire release carried by Fidelity and Reuters’ report as sources. The required checker prints `ok`.
Completed [artifacts/answer.json](/root/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json). Answer: 17 USD per share. Source named in the artifact: BioPharma Dive. Validation passed: `ok`.
ADARx priced the upsized IPO at **$17 per share**. I used the company’s press release distributed by GlobeNewswire, with Reuters as corroboration. The answer is in [artifacts/answer.json](/home/imd-worker/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json), and the required checker printed `ok`.
The answer is **$17 per share**, as stated in ADARx Pharmaceuticals’ [official September 24, 2026 release](https://investors.adarx.com/news-releases/news-release-details/adarx-pharmaceuticals-announces-pricing-upsized-4463-million). Wrote [artifacts/answer.json](/home/imd/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json). The required checker printed `ok`.
ADARx priced the upsized IPO at **$17 per share**. The company press release syndicated by [Fidelity](https://www.fidelity.com/news/article/default/202609241933PRIMZONEFULLFEED9833794) reports that price; [Reuters](https://www.fidelity.com/news/article/default/202609241934RTRSNEWSCOMBINED_TUA5JMMDX_1) confirms it. Created [artifacts/answer.json](/home/imd2/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json). The required checker printed `ok`.
ADARx priced the upsized IPO at **$17 per share**. The answer file is complete, and the checker printed `ok`. [artifacts/answer.json](/home/imd/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json) · [Fidelity-hosted GlobeNewswire announcement](https://www.fidelity.com/news/article/default/202609241933PRIMZONEFULLFEED9833794)
Checker prints `ok`. The answer is $17 per share, sourced from BioSpace's press release and corroborated by Bloomberg — [BioSpace](https://www.biospace.com/press-releases/adarx-pharmaceuticals-announces-pricing-of-upsized-446-3-million-initial-public-offering), [Bloomberg](https://www.bloomberg.com/news/articles/2026-09-25/adarx-pharma-shares-climb-30-after-446-3-million-upsized-ipo). Written to `artifacts/answer.json` with recipe kind `panel`.
Created [artifacts/answer.json](/opt/identitymd/worker3/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json) with the answer **17**, supported by [Reuters](https://www.fidelity.com/news/article/default/202609241934RTRSNEWSCOMBINED_TUA5JMMDX_1) and the [company’s GlobeNewswire release](https://www.fidelity.com/news/article/default/202609241933PRIMZONEFULLFEED9833794). The supplied checker prints `ok`.
ADARx priced the upsized IPO at **$17 per share**. I recorded the answer in [artifacts/answer.json](/home/imd/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json); the checker printed `ok`. Source: [Reuters report via Fidelity](https://www.fidelity.com/news/article/default/202609241934RTRSNEWSCOMBINED_TUA5JMMDX_1).
Created [artifacts/answer.json](/home/imd/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json) with the answer **$17 per share**, citing the GlobeNewswire release republished on Fidelity. The checker prints `ok`.
Created [artifacts/answer.json](/home/imd-worker/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json) with the answer **$17 per share**. The supplied checker passes: `ok`.
Created [artifacts/answer.json](/root/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json) with the answer **$17 per share**, based on [ADARx’s September 24 press release](https://investors.adarx.com/news-releases/news-release-details/adarx-pharmaceuticals-announces-pricing-upsized-4463-million). The required checker printed `ok`.
Answer: **$17 per share**, reported by [Reuters](https://www.fidelity.com/news/article/default/202609241934RTRSNEWSCOMBINED_TUA5JMMDX_1). Created `artifacts/answer.json` with the pinned identifiers and panel source. The required checker printed `ok`.
ADARx priced the upsized IPO at **$17 per share**. The company release carried by [Fidelity](https://www.fidelity.com/news/article/default/202609241933PRIMZONEFULLFEED9833794) and a [Reuters brief](https://www.fidelity.com/news/article/default/202609241934RTRSNEWSCOMBINED_TUA5JMMDX_1) report that price. I wrote [artifacts/answer.json](/home/seat20/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json). The required checker printed `ok`.
ADARx priced the upsized IPO at **$17 per share**. I wrote the answer to [artifacts/answer.json](/root/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json), citing the [company announcement carried by GlobeNewswire](https://www.globenewswire.com/news-release/2026/09/24/3368818/0/en/adarx-pharmaceuticals-announces-pricing-of-upsized-446-3-million-initial-public-offering.html). The checker printed `ok`.
The answer is **$17 per share**. ADARx’s company announcement distributed by [GlobeNewswire](https://www.globenewswire.com/news-release/2026/09/24/3368818/0/en/adarx-pharmaceuticals-announces-pricing-of-upsized-446-3-million-initial-public-offering.html) states the price; Reuters independently reported the same figure. [answer.json](/home/identitymd/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json) is written, and the required checker printed `ok`.
ADARx priced the upsized IPO at **$17 per share**. I recorded the Reuters report carried by [Investing.com](https://www.investing.com/news/company-news/adarx-pharmaceuticals-prices-upsized-ipo-at-17-per-share-93CH-4916428) in [artifacts/answer.json](/root/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json). The specified checker printed `ok`.
ADARx priced its upsized IPO at **$17 per share**, according to its [September 24 investor relations release](https://investors.adarx.com/news-releases/news-release-details/adarx-pharmaceuticals-announces-pricing-upsized-4463-million). I wrote the answer to [artifacts/answer.json](/home/ubuntu/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json). The required checker printed `ok`.
ADARx priced the upsized IPO at **$17 per share**. Reuters’ report syndicated by Investing.com states the price was $17.00 per share. [Source](https://www.investing.com/news/company-news/adarx-pharmaceuticals-prices-upsized-ipo-at-17-per-share-93CH-4916428) Saved the answer in [artifacts/answer.json](/root/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json). The required checker printed `ok`.
Answered **$17 per share** in [artifacts/answer.json](/home/seat13/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json), citing ADARx’s [official investor relations release](https://investors.adarx.com/news-releases/news-release-details/adarx-pharmaceuticals-announces-pricing-upsized-4463-million). The required checker passed: `ok`.
Wrote [artifacts/answer.json](/home/imd/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json) with the answer **$17 per share**, citing ADARx’s official investor relations release. The specified checker printed `ok`.
ADARx priced the IPO at **$17 per share**. The Reuters report republished by [Investing.com](https://www.investing.com/news/company-news/adarx-pharmaceuticals-prices-upsized-ipo-at-17-per-share-93CH-4916428) states the offering was priced at $17.00 per share. [answer.json](/home/imd/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json) is written, and the checker printed `ok`.
Checker prints `ok`. The answer artifact is complete: ADARx priced its upsized IPO at **$17 per share** on September 24, 2026 (confirmed via the company's GlobeNewswire press release and Bloomberg).
ADARx priced the upsized IPO at **$17 per share**. The company’s [September 24 investor relations release](https://investors.adarx.com/news-releases/news-release-details/adarx-pharmaceuticals-announces-pricing-upsized-4463-million) states the price was $17.00. Created `artifacts/answer.json`; the checker prints `ok`.
Checker prints `ok`. Answer: ADARx Pharmaceuticals priced its upsized IPO at **$17.00/share** (26.25M shares, $446.3M raised), confirmed via BioSpace and IPOScoop. `artifacts/answer.json` is written and validated.
Created [artifacts/answer.json](/home/identitymd/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json) with the answer **$17 per share**, supported by ADARx’s investor relations release. The specified checker prints `ok`.
`artifacts/answer.json` records the IPO price as **$17 per share**, citing ADARx Pharmaceuticals’ September 24, 2026 investor relations release. The supplied checker prints `ok`.
The IPO price was **$17 per share**. I recorded the cited ADARx/GlobeNewswire release and Reuters report in [answer.json](/home/imd/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json). The checker printed `ok`.
ADARx priced the upsized IPO at **$17 per share**, reported by [Reuters via Investing.com](https://www.investing.com/news/company-news/adarx-pharmaceuticals-prices-upsized-ipo-at-17-per-share-93CH-4916428). Created [artifacts/answer.json](/home/imd-worker/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json). The checker printed `ok`.
The upsized IPO was priced at **$17 per share**. Fidelity’s page carries the September 24 GlobeNewswire release with that price, and ADARx’s site lists the announcement that day ([Fidelity](https://www.fidelity.com/news/article/default/202609241933PRIMZONEFULLFEED9833794), [ADARx](https://www.adarx.com/)). I wrote [artifacts/answer.json](/home/seat19/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json) with the pinned request details and panel source. The supplied checker printed `ok`.
Answered **$17 per share**. The source is ADARx’s [official investor relations release](https://investors.adarx.com/news-releases/news-release-details/adarx-pharmaceuticals-announces-pricing-upsized-4463-million), which reports $17.00 per share. [answer.json](/home/imd-worker/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json) passes the required checker (`ok`).
The IPO price was **$17 per share**. The official [ADARx press release](https://investors.adarx.com/news-releases/news-release-details/adarx-pharmaceuticals-announces-pricing-upsized-4463-million) reports $17.00 per share. Created [artifacts/answer.json](/home/seat8/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json). The required checker printed `ok`.
Checker prints `ok`. artifacts/answer.json is complete: ADARx Pharmaceuticals priced its upsized IPO at **$17.00 per share** on September 24, 2026 (26,250,000 shares, ~$446.3M raised), per the GlobeNewswire official press release, corroborated by Bloomberg and BioSpace.
ADARx priced the upsized IPO at **$17 per share**, according to its [official investor relations release](https://investors.adarx.com/news-releases/news-release-details/adarx-pharmaceuticals-announces-pricing-upsized-4463-million). Created [artifacts/answer.json](/home/identitymd4/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json). The required checker printed `ok`.
The official ADARx investor relations release reports an IPO price of **$17 per share**. I wrote the answer to [artifacts/answer.json](/root/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1a43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json); the required checker printed `ok`.
The answer is **$17 per share**. I recorded ADARx’s September 24 investor relations release as the source in [artifacts/answer.json](/home/imd-worker/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json). The required checker printed `ok`.
ADARx priced the upsized IPO at **$17 per share**. The required checker passed. The answer and source are recorded in [artifacts/answer.json](/home/identitymd7/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json). [ADARx’s September 24 release](https://investors.adarx.com/news-releases/news-release-details/adarx-pharmaceuticals-announces-pricing-upsized-4463-million) states the offering price was $17.00 per share.
ADARx priced its upsized IPO at **$17 per share**. The answer is recorded in [artifacts/answer.json](/home/imd/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json), and the checker returned `ok`.
ADARx priced the upsized IPO at **$17 per share**, as stated in its [September 24 company release](https://investors.adarx.com/news-releases/news-release-details/adarx-pharmaceuticals-announces-pricing-upsized-4463-million). [artifacts/answer.json](/home/identitymd5/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json) is written, and the checker prints `ok`.
ADARx priced the upsized IPO at **$17 per share**, according to its [official investor release](https://investors.adarx.com/news-releases/news-release-details/adarx-pharmaceuticals-announces-pricing-upsized-4463-million). I wrote [artifacts/answer.json](/Users/dannyren/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json) and the checker printed `ok`.
Checker prints `ok` and `git status --porcelain` is clean. Answer: ADARx priced its upsized IPO at **$17 per share** (GlobeNewswire, confirmed by Bloomberg), written to `artifacts/answer.json`.
Created [artifacts/answer.json](/root/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json) with the answer **$17 per share**, sourced from ADARx’s official investor release. The specified checker prints `ok`.
The IPO price was **$17 per share**. I cited ADARx’s [September 24 investor relations release](https://investors.adarx.com/news-releases/news-release-details/adarx-pharmaceuticals-announces-pricing-upsized-4463-million) in [artifacts/answer.json](/home/worker/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json). The checker printed `ok`.
Checker prints `ok`. artifacts/answer.json is complete: ADARx priced its upsized IPO at $17.00/share on Sept 24, 2026 (per BioSpace/GlobeNewswire release, corroborated by Investing.com and Yahoo Finance).
Checker prints `ok`. answer.json is written with answer `17` (price per share), sourced from Bloomberg and the company's press release (via BioSpace/GlobeNewswire).
ADARx priced the upsized IPO at **$17 per share**. I cited the company’s September 24 release and noted Reuters’ corroboration in [artifacts/answer.json](/root/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json). The checker passed: `ok`.
Check passes. artifacts/answer.json is written with answer "17" (whole-dollar IPO price), sourced from the GlobeNewswire/BioSpace press release and corroborated by Bloomberg News, both dated September 24, 2026.
ADARx priced the upsized IPO at **$17 per share**. The answer file cites the company’s September 24 press release and passes the checker (`ok`): [artifacts/answer.json](/home/imd-worker/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json).
Created [artifacts/answer.json](/home/identitymd6/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json) with the answer **$17 per share**, sourced from ADARx’s [September 24 pricing release](https://investors.adarx.com/news-releases/news-release-details/adarx-pharmaceuticals-announces-pricing-upsized-4463-million). The supplied checker prints `ok`.
The reported whole-dollar IPO price was **$17 per share**. I recorded the Fidelity-carried GlobeNewswire release as the source in [artifacts/answer.json](/home/imd/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json). The required checker printed `ok`.
Checker prints `ok`. artifacts/answer.json reports ADARx's upsized IPO priced at **$17 per share** (Sept 24, 2026), sourced from ADARx's press release (via BioSpace/Yahoo Finance) and corroborated by Bloomberg.
ADARx priced the upsized IPO at **$17 per share**, according to its [official September 24, 2026 announcement](https://investors.adarx.com/news-releases/news-release-details/adarx-pharmaceuticals-announces-pricing-upsized-4463-million). Wrote [artifacts/answer.json](/home/imd/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json). The required checker printed `ok`.
Wrote [artifacts/answer.json](/home/imd/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json) with the answer **$17 per share**, based on [ADARx’s investor relations release](https://investors.adarx.com/news-releases/news-release-details/adarx-pharmaceuticals-announces-pricing-upsized-4463-million). The required checker printed `ok`.
Checker passes. ADARx priced its upsized IPO at $17.00/share (26,250,000 shares, ~$446.3M raised), per GlobeNewswire/Bloomberg — answer written to `artifacts/answer.json` with recipe kind "panel".
ADARx priced the upsized IPO at **$17 per share**, according to its [September 24 investor relations release](https://investors.adarx.com/news-releases/news-release-details/adarx-pharmaceuticals-announces-pricing-upsized-4463-million). The Reuters brief carried by Fidelity reports the same price. Created [artifacts/answer.json](/home/imd/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json). The checker printed `ok`.
Checker passes (`ok`) and `git status --porcelain` is clean. artifacts/answer.json is written with answer $17/share, sourced from ADARx's official press release (BioSpace/GlobeNewswire), and left untracked as required.
`artifacts/answer.json` contains the answer **$17 per share**, based on ADARx’s [official September 24 announcement](https://investors.adarx.com/news-releases/news-release-details/adarx-pharmaceuticals-announces-pricing-upsized-4463-million). The checker printed `ok`.
The IPO price was **$17 per share**. I recorded it in [artifacts/answer.json](/root/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json), citing [ADARx’s official release](https://investors.adarx.com/news-releases/news-release-details/adarx-pharmaceuticals-announces-pricing-upsized-4463-million). The required checker printed `ok`.
ADARx priced the upsized IPO at **$17 per share**. Its [September 24 investor relations release](https://investors.adarx.com/news-releases/news-release-details/adarx-pharmaceuticals-announces-pricing-upsized-4463-million) states the price was $17.00 per share. Saved the answer in [artifacts/answer.json](/home/imd/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json). The required checker printed `ok`.
ADARx priced the upsized IPO at **$17 per share**. I recorded the answer and cited the company’s September 24 press release in [answer.json](/home/imd/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json). The supplied checker prints `ok`.
Recorded the answer as **$17 per share**, based on ADARx’s September 24, 2026 [pricing announcement](https://investors.adarx.com/news-releases/news-release-details/adarx-pharmaceuticals-announces-pricing-upsized-4463-million). The checker passed (`ok`). [artifacts/answer.json](/home/seat15/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json)
`artifacts/answer.json` contains the answer **17** (USD per share), based on ADARx Pharmaceuticals’ official September 24, 2026 announcement. The checker prints `ok`.
Checker prints `ok`. Answer: ADARx Pharmaceuticals priced its upsized IPO at $17.00/share (high end of $15–$17 range), confirmed by [Bloomberg](https://www.bloomberg.com/news/articles/2026-09-24/adarx-pharmaceuticals-raises-446-3-million-in-upsized-us-ipo) and the company's press release via [BioSpace/GlobeNewswire](https://www.biospace.com/press-releases/adarx-pharmaceuticals-announces-pricing-of-upsized-446-3-million-initial-public-offering). Written to `artifacts/answer.json`.
Completed [artifacts/answer.json](/root/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json) with the answer **$17 per share**, citing Fidelity’s republication of the GlobeNewswire company announcement. The checker printed `ok`.
Checker prints `ok`. artifacts/answer.json is written with answer 17 (USD/share), sourced from Bloomberg and ADARx's own press release (via BioSpace).
The IPO price was **$17 per share**. I recorded the official ADARx release as the source in [artifacts/answer.json](/home/imd/.identitymd-1838/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json). The required checker printed `ok`.
Wrote [artifacts/answer.json](/root/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1a43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json) with the answer **$17 per share**, based on ADARx’s [official September 24 press release](https://investors.adarx.com/news-releases/news-release-details/adarx-pharmaceuticals-announces-pricing-upsized-4463-million). The checker printed `ok`.
The answer is **$17 per share**. ADARx’s [September 24, 2026 investor relations release](https://investors.adarx.com/news-releases/news-release-details/adarx-pharmaceuticals-announces-pricing-upsized-4463-million) states the IPO price was $17.00 per share. Created [artifacts/answer.json](/home/identitymd3/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json). The checker printed `ok`.
Checker prints `ok`. `artifacts/answer.json` is written: ADARx priced its upsized IPO at **$17 per share** (high end of $15–$17 range, 26.25M shares, $446.3M raised), sourced from Bloomberg and ADARx's own press release (via BioSpace/GlobeNewswire).
Checker prints `ok`. `artifacts/answer.json` reports ADARx Pharmaceuticals priced its upsized IPO at **$17.00 per share** (26,250,000 shares, ~$446.3M gross), sourced from BioSpace's press release and corroborated by Bloomberg.
ADARx priced its upsized IPO at **$17 per share**. The answer is recorded in [artifacts/answer.json](/home/imd/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json), citing the company’s September 24 release. The supplied checker printed `ok`.
ADARx priced the upsized IPO at **$17 per share**. Its [official September 24, 2026 release](https://investors.adarx.com/news-releases/news-release-details/adarx-pharmaceuticals-announces-pricing-upsized-4463-million) states the price was $17.00 per share. I wrote [artifacts/answer.json](/root/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json). The required checker printed `ok`.
Checker prints "ok" and git status is clean (artifacts/ is untracked output, not staged). Task complete: ADARx priced its upsized IPO at $17 per share on September 24, 2026, per the company's GlobeNewswire/BioSpace release and corroborated by IPOScoop.
The IPO price was **$17 per share**. I recorded the answer in [artifacts/answer.json](/root/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1a43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json), citing ADARx’s September 24 investor relations release. The checker printed `ok`.
ADARx priced the upsized IPO at **$17 per share**. The official [ADARx investor relations release](https://investors.adarx.com/news-releases/news-release-details/adarx-pharmaceuticals-announces-pricing-upsized-4463-million) confirms the price. Created [artifacts/answer.json](/home/imd-worker/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json). The required checker printed `ok`.
Checker passes with `ok`. Answer: ADARx priced its upsized IPO at **$17 per share** (per BioSpace/GlobeNewswire press release, corroborated by Bloomberg), written to `artifacts/answer.json` as a panel recipe.
ADARx priced the upsized IPO at **$17 per share**. I recorded the company’s September 24, 2026 announcement as the source in [answer.json](/home/imd-worker/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json). The required checker printed `ok`.
Checker prints `ok`. artifacts/answer.json written with answer $17/share, sourced from BioSpace/GlobeNewswire's press release on ADARx's upsized IPO pricing.
ADARx’s official September 24 release reports an IPO price of $17.00 per share. I wrote `"17"` to [artifacts/answer.json](/home/seat10/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d6043fbec166/artifacts/answer.json) and the checker printed `ok`.
Checker prints `ok`. ADARx priced its upsized IPO at $17 per share (confirmed via Investing.com and BioSpace); `artifacts/answer.json` is written and validated.
ADARx priced the upsized IPO at **$17 per share**. The Reuters report carried by Investing.com states $17.00 per share. I wrote [artifacts/answer.json](/home/imd-worker/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json) and the provided checker returned `ok`.
Checker printed `ok`. artifacts/answer.json is complete: ADARx priced its upsized IPO at $17/share on 2026-09-24 (per ADARx's own GlobeNewswire release and Bloomberg), recorded as a `panel` recipe with that source.
ADARx priced the upsized IPO at **$17 per share**. Fidelity’s page carries the company’s GlobeNewswire release, which reports the price; Investing.com independently reports the same figure. The answer is saved in [artifacts/answer.json](/home/imd-worker/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json). The required checker printed `ok`.
Checker prints "ok". artifacts/answer.json is complete: $17 per share, sourced from the GlobeNewswire press release (corroborated by Bloomberg).
Checker prints `ok`. Answer: ADARx priced its upsized IPO at $17.00 per share on September 24, 2026 (per BioSpace/GlobeNewswire release, corroborated by IPOScoop), written to `artifacts/answer.json`.
ADARx priced its upsized IPO at **$17 per share**, and `artifacts/answer.json` is written. The checker prints `ok`. The source is ADARx's GlobeNewswire press release of 2026-09-24. It states 26,250,000 shares at $17.00, the top of the $15–$17 range. Investing.com and Renaissance Capital report the same price. I only read the web search result summaries. I did not open the press release page itself. The file's `notes` field says this. The answer is a reported news fact, so it uses a `panel` recipe with the press release as its source. It has nothing to do with the pinned block range beyond timestamping the request.
ADARx priced its upsized IPO at **$17.00 per share**, so the answer is 17. The ADARx press release (as carried by BioSpace) and Investing.com both report 26,250,000 shares at that price. Gross proceeds were about $446.3M, and trading began on Nasdaq on September 25, 2026. I read these through search results only and did not open the full articles. `artifacts/answer.json` uses a "panel" recipe naming the BioSpace press release as the source. The checker printed `ok`. The window is copied exactly from `oracle.json`. Sources: - [ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering (BioSpace)](https://www.biospace.com/press-releases/adarx-pharmaceuticals-announces-pricing-of-upsized-446-3-million-initial-public-offering) - [ADARx Pharmaceuticals prices upsized IPO at $17 per share (Investing.com)](https://www.investing.com/news/company-news/adarx-pharmaceuticals-prices-upsized-ipo-at-17-per-share-93CH-4916428)
Checker prints `ok`. artifacts/answer.json is written with answer `17` (ADARx Pharmaceuticals priced its upsized IPO at $17.00/share on Sept 24, 2026), sourced from the company's press release (via BioSpace/GlobeNewswire), corroborated by Bloomberg.
The IPO price was **$17 per share**. I recorded the answer and source in [artifacts/answer.json](/home/imd3/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json). The required checker returned `ok`.
ADARx priced its upsized IPO at $17.00 per share, so the answer is 17. I wrote `artifacts/answer.json`, and the checker prints `ok` for it. The source is ADARx's own pricing press release on GlobeNewswire, dated September 24, 2026. It says 26,250,000 shares priced at $17.00, for about $446.3 million gross. Investing.com's headline also gives $17 per share. The recipe is kind `panel` and cites the GlobeNewswire link. The checker rejected the first version because the `window` keys were in the wrong order. I reordered them to match `.imd/reads/oracle.json` and it then passed.
ADARx priced its upsized IPO at $17 per share, and I wrote `artifacts/answer.json` with that answer. `check-answer.mjs` prints ok for it. The source is the company's [GlobeNewswire press release](https://www.globenewswire.com/news-release/2026/09/24/3368818/0/en/adarx-pharmaceuticals-announces-pricing-of-upsized-446-3-million-initial-public-offering.html), which states 26,250,000 shares priced at $17.00, for about $446.3 million in gross proceeds. The [Investing.com](https://www.investing.com/news/company-news/adarx-pharmaceuticals-prices-upsized-ipo-at-17-per-share-93CH-4916428) headline gives the same $17 figure. The search results also showed a [Bloomberg](https://www.bloomberg.com/news/articles/2026-09-25/adarx-pharma-shares-climb-30-after-446-3-million-upsized-ipo) headline on the $446.3 million upsized IPO, which I did not open. I read only the search-result snippets, not the full pages. The recipe is kind `panel` with the press release URL as the source.
ADARx priced its upsized IPO at $17 per share, and `artifacts/answer.json` now says so. `check-answer.mjs` prints ok for it. The source is the [GlobeNewswire pricing release](https://www.globenewswire.com/news-release/2026/09/24/3368818/0/en/adarx-pharmaceuticals-announces-pricing-of-upsized-446-3-million-initial-public-offering.html). It reports 26,250,000 shares at $17.00, about $446.3 million gross. [Investing.com](https://www.investing.com/news/company-news/adarx-pharmaceuticals-prices-upsized-ipo-at-17-per-share-93CH-4916428) and [BioSpace](https://www.biospace.com/press-releases/adarx-pharmaceuticals-announces-pricing-of-upsized-446-3-million-initial-public-offering) carry the same figure. I only read the search-result summaries of these pages, not the full pages. The file uses the `panel` recipe with that release as its source. The chain, window and closing hash are copied exactly from `oracle.json`. The checker first rejected the file because the window keys were in the wrong order, so I reordered them.
ADARx priced its upsized IPO at $17 per share. I wrote `artifacts/answer.json` with answer "17", and the checker printed `ok`. The source is ADARx's own press release on GlobeNewswire, dated September 24, 2026. It says 26,250,000 shares were priced at $17.00 each, for about $446.3 million gross. A search result snippet from Investing.com reported the same $17 price. I did not open either page in full; I read the release only as a search-result summary. The recipe is kind `panel` with that release as the source. The window and request id are copied from `.imd/reads/oracle.json`.
Checker prints `ok`. Answer: ADARx priced its upsized IPO at $17.00/share (26,250,000 shares, ~$446.3M raised), per Bloomberg and ADARx's own press release. Written to `artifacts/answer.json`.
ADARx priced its upsized IPO at $17 per share. I wrote `artifacts/answer.json` with answer "17", and `check-answer.mjs` prints ok. The company's pricing press release, carried by [BioSpace](https://www.biospace.com/press-releases/adarx-pharmaceuticals-announces-pricing-of-upsized-446-3-million-initial-public-offering), says 26,250,000 shares at $17.00 per share, about $446.3 million gross. [Investing.com](https://www.investing.com/news/company-news/adarx-pharmaceuticals-prices-upsized-ipo-at-17-per-share-93CH-4916428) reports the same price. I only had web search results for these, not the full pages. The recipe is kind "panel", citing the BioSpace release as its source. The first check failed because the window keys were in the wrong order (`toBlock` must come first). I reordered them, and the request id, chain and window now match `oracle.json`.
ADARx priced its upsized IPO at $17 per share, so the answer is 17. `artifacts/answer.json` is written with a `panel` recipe, and the checker prints `ok`. The source is [ADARx's pricing press release on GlobeNewswire](https://www.globenewswire.com/news-release/2026/09/24/3368818/0/en/adarx-pharmaceuticals-announces-pricing-of-upsized-446-3-million-initial-public-offering.html), dated September 24, 2026. It says 26,250,000 shares priced at $17.00 each, for about $446.3 million in gross proceeds. I only saw the release through the search result summary and did not open the page itself. An [Investing.com headline](https://www.investing.com/news/company-news/adarx-pharmaceuticals-prices-upsized-ipo-at-17-per-share-93CH-4916428) in the same results also says $17. The checker first rejected the file because the `window` keys were in the wrong order. I reordered them to match `oracle.json` and it passed.
Recorded the answer as **$17 per share** from ADARx’s [official investor relations release](https://investors.adarx.com/news-releases/news-release-details/adarx-pharmaceuticals-announces-pricing-upsized-4463-million). The required checker passed (`ok`). [answer.json](/home/debian/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json)
Created [artifacts/answer.json](/root/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json) with answer `17` (USD per share), citing Reuters via Fidelity. Validation passed: `ok`.
Created [artifacts/answer.json](/root/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json) with answer `17`. Validation passed: `check-answer.mjs` printed `ok`. The cited primary ADARx release reports $17.00 per share. [Source](https://investors.adarx.com/news-releases/news-release-details/adarx-pharmaceuticals-announces-pricing-upsized-4463-million)
Created [artifacts/answer.json](/root/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json) with answer `17`. Verified against ADARx’s [official September 24 release](https://investors.adarx.com/news-releases/news-release-details/adarx-pharmaceuticals-announces-pricing-upsized-4463-million) and Reuters. The required checker prints `ok`.
Completed [artifacts/answer.json](/root/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json). Answer: `17` (USD per share), sourced from ADARx’s September 24, 2026 investor-relations release. Validation passed: `check-answer.mjs` printed `ok`.
Created [artifacts/answer.json](/root/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json) with the panel-sourced answer: `$17` per share. Validator result: `ok`.
ADARx priced the upsized IPO at **$17 per share**, according to its [September 24 investor relations release](https://investors.adarx.com/news-releases/news-release-details/adarx-pharmaceuticals-announces-pricing-upsized-4463-million). Created [artifacts/answer.json](/home/imdworker/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json). The supplied checker printed `ok`.
ADARx priced the upsized IPO at **$17 per share**. Its [September 24 investor relations release](https://investors.adarx.com/news-releases/news-release-details/adarx-pharmaceuticals-announces-pricing-upsized-4463-million) states the price was $17.00. I wrote [artifacts/answer.json](/home/imdworker/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json). The required checker printed `ok`.
Created [artifacts/answer.json](/root/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json) with answer `17`. Validated successfully: `check-answer.mjs` printed `ok`. The cited GlobeNewswire company release reports $17.00 per share. [Source](https://www.fidelity.com/news/article/default/202609241933PRIMZONEFULLFEED9833794)
Created [artifacts/answer.json](/root/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json) with answer `17`. Verified with the required checker: `ok`. Source: [ADARx official IPO pricing release](https://investors.adarx.com/news-releases/news-release-details/adarx-pharmaceuticals-announces-pricing-upsized-4463-million).
Created [artifacts/answer.json](/home/imdworker/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json) with answer `17`, citing ADARx’s official release. Validation passed: `ok`.
Checker prints `ok` and `git status --porcelain` is clean. Answer: ADARx priced its upsized IPO at **$17.00/share** on Sept 24, 2026 (per BioSpace/GlobeNewswire and IPOScoop). `artifacts/answer.json` is written and passes the checker.
Created [artifacts/answer.json](/root/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json) with answer `17`, citing ADARx’s official release. Validation passed: `ok`.
The answer is **$17 per share**. I recorded it in [artifacts/answer.json](/root/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json). The source is ADARx’s [September 24 investor relations release](https://investors.adarx.com/news-releases/news-release-details/adarx-pharmaceuticals-announces-pricing-upsized-4463-million), and the required checker printed `ok`.
Created [artifacts/answer.json](/root/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json) with answer `17`. Validated successfully: `check-answer.mjs` printed `ok`. Source: [ADARx issuer release](https://investors.adarx.com/news-releases/news-release-details/adarx-pharmaceuticals-announces-pricing-upsized-4463-million).
Created [artifacts/answer.json](/root/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json) with answer `17`, citing ADARx’s primary press release. Validation passed: `ok`.
Checker prints `ok` and git status is clean (artifacts/ is untracked/output, not staged). Answer: ADARx priced its upsized IPO at **$17 per share** on September 24, 2026, per BioSpace/GlobeNewswire and Bloomberg. `artifacts/answer.json` is written and validated.
Clean. Task complete: `artifacts/answer.json` written with answer 17 (ADARx priced its upsized IPO at $17/share on 2026-09-24, per BioSpace/GlobeNewswire and Bloomberg), and the checker confirms it's valid.
ADARx priced its upsized IPO at **$17 per share**. The [company’s September 24 release](https://investors.adarx.com/news-releases/news-release-details/adarx-pharmaceuticals-announces-pricing-upsized-4463-million) states $17.00 per share. [artifacts/answer.json](/var/lib/imd-worker/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json) is written, and the checker prints `ok`.
ADARx priced the upsized IPO at **$17 per share**. The company’s [official September 24 announcement](https://investors.adarx.com/news-releases/news-release-details/adarx-pharmaceuticals-announces-pricing-upsized-4463-million) states $17.00 per share; Reuters independently reported the same price. I wrote [artifacts/answer.json](/root/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json). The required checker printed `ok`.
The IPO was priced at **$17 per share**. I wrote [artifacts/answer.json](/home/levi/imd/p6/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json) with the Reuters report carried by Fidelity as the source and ADARx’s company release as corroboration. The checker prints `ok`.
Checker prints "ok" and `git status --porcelain` is clean. Answer: ADARx priced its upsized IPO at $17.00 per share (GlobeNewswire release, corroborated by Bloomberg). `artifacts/answer.json` is written and validated.
The answer is **$17 per share**, based on ADARx’s official investor release. [artifacts/answer.json](/home/imd/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json) is written, and the checker prints `ok`.
Checker prints "ok" and `git status --porcelain` is clean (artifacts/ is untracked/ignored). Answer: ADARx priced its upsized IPO at **$17/share**, written to `artifacts/answer.json`, sourced from ADARx's press release and IPOScoop.
Checker prints `ok`. Answer: ADARx Pharmaceuticals priced its upsized IPO at $17.00/share on September 24, 2026 (per BioSpace/GlobeNewswire press release and Bloomberg), written to `artifacts/answer.json`.
Checker passes. `artifacts/answer.json` is written with the answer $17 (ADARx Pharmaceuticals' upsized IPO price per share, priced September 24, 2026), sourced from ADARx's press release (BioSpace/GlobeNewswire) and corroborated by Bloomberg and IPOScoop, using the `panel` recipe.
Checker prints "ok" and git status is clean (artifacts/ untracked output as expected). ADARx Pharmaceuticals priced its upsized IPO at $17.00/share on Sept 24, 2026, per GlobeNewswire/BioSpace and Investing.com. Answer written to artifacts/answer.json.
Done. `artifacts/answer.json` answers $17/share for ADARx Pharmaceuticals' upsized IPO (Sept 24, 2026), sourced from GlobeNewswire and corroborated by IPOScoop/Bloomberg. Checker prints `ok`, and `git status --porcelain` is clean (artifacts/ is untracked output, not committed).
The answer is **$17 per share**. ADARx’s [September 24 pricing announcement](https://investors.adarx.com/news-releases/news-release-details/adarx-pharmaceuticals-announces-pricing-upsized-4463-million) states the price was $17.00 per share. Created `artifacts/answer.json` with the pinned request window and panel source. The required checker printed `ok`.
The IPO price was **$17 per share**. I recorded the answer in [artifacts/answer.json](/root/.identitymd/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json), citing [ADARx’s investor relations release](https://investors.adarx.com/news-releases/news-release-details/adarx-pharmaceuticals-announces-pricing-upsized-4463-million). The checker printed `ok`.
Checker passes with "ok" and git status is clean (artifacts/answer.json is untracked/gitignored as expected). Answer: ADARx priced its upsized IPO at $17.00/share, confirmed by Bloomberg and BioSpace.
Checker prints "ok" and git status is clean (artifacts/ untracked as expected, not shown since it's outside repo scope tracking). Task complete: ADARx priced its upsized IPO at $17 per share, answer written to `artifacts/answer.json`.
The IPO price was **$17 per share**. The company announcement carried by Fidelity’s GlobeNewswire feed states $17.00 per share; Reuters also reported $17. [artifacts/answer.json](/home/levi/imd/p8/work/3e2c8166-d1a4-4226-a87c-19f1c43296a3/e4d68acb-4780-43a2-aab7-d604f3bec166/artifacts/answer.json) is written, and the required checker printed `ok`.
Checker prints `ok`. ADARx priced its upsized IPO at $17.00/share on 2026-09-24, per BioSpace and Investing.com; `artifacts/answer.json` written with answer "17" and panel recipe.
ADARx priced its upsized IPO at $17 per share. I wrote `artifacts/answer.json` with answer "17", and the checker prints `ok`. The source is the company's own press release on GlobeNewswire dated 2026-09-24. It reports 26,250,000 shares at $17.00 each, for $446.3 million gross. Investing.com and Bloomberg headlines corroborate the price, but I only saw their headlines in search results, not the articles. The recipe is kind "panel" with the GlobeNewswire link as its source. The first checker run failed on key order in the `window` object, so I reordered it to match `oracle.json` exactly.
ADARx priced its upsized IPO at $17 per share. I wrote `artifacts/answer.json` with that answer, and `check-answer.mjs` prints ok. The source is ADARx's pricing press release, carried by [BioSpace](https://www.biospace.com/press-releases/adarx-pharmaceuticals-announces-pricing-of-upsized-446-3-million-initial-public-offering). It reports 26,250,000 shares at $17.00, for about $446.3 million gross. [Investing.com](https://www.investing.com/news/company-news/adarx-pharmaceuticals-prices-upsized-ipo-at-17-per-share-93CH-4916428) also reports $17. I only read the search-result summaries, not the full pages. The recipe is kind `panel` with that BioSpace URL as the source.
ADARx priced its upsized IPO at **$17 per share**, and `artifacts/answer.json` is written. The checker prints `ok`. The source is ADARx's own press release on [GlobeNewswire](https://www.globenewswire.com/news-release/2026/09/24/3368818/0/en/adarx-pharmaceuticals-announces-pricing-of-upsized-446-3-million-initial-public-offering.html), dated September 24, 2026. It gives 26,250,000 shares at $17.00, for about $446.3 million gross. I read that in a web search summary rather than opening the page itself. [Renaissance Capital](https://www.renaissancecapital.com/IPO-Center/News/121878/sirna-biotech-adarx-pharmaceuticals-prices-upsized-ipo-at-17-the-high-end) and [Investing.com](https://www.investing.com/news/company-news/adarx-pharmaceuticals-prices-upsized-ipo-at-17-per-share-93CH-4916428) report the same price. The recipe kind is `panel`, with the press release as its source. The window is copied exactly from the brief. My first write had the window keys in a different order and the checker rejected it, so I reordered them.
Checker prints `ok`. artifacts/answer.json is written with answer $17/share, sourced from BioSpace and Bloomberg.
ADARx priced its upsized IPO at $17 per share. I wrote `artifacts/answer.json` with the answer "17", and the checker prints ok. The source is ADARx's own pricing press release, as carried by BioSpace. It says 26,250,000 shares were priced at $17.00, for gross proceeds of about $446.3 million. I also saw Investing.com's report, which agrees. Both came from search results; I didn't open either page. Sources: - [BioSpace press release](https://www.biospace.com/press-releases/adarx-pharmaceuticals-announces-pricing-of-upsized-446-3-million-initial-public-offering) - [Investing.com](https://www.investing.com/news/company-news/adarx-pharmaceuticals-prices-upsized-ipo-at-17-per-share-93CH-4916428)
ADARx priced its upsized IPO at $17 per share. I wrote `artifacts/answer.json` with answer `"17"` and a panel recipe, and the checker prints ok. The source is ADARx's own press release on GlobeNewswire, dated September 24, 2026. It says 26,250,000 shares were priced at $17.00, the high end of the $15–$17 range. Investing.com and IPOScoop report the same price, though I only saw their search-result summaries, not the full articles. The window and hash are copied from `.imd/reads/oracle.json`. The first checker run failed because my window keys were in the wrong order; I reordered them to match.
ADARx priced its upsized IPO at $17 per share. `artifacts/answer.json` is written with answer "17", and the checker prints `ok`. The [GlobeNewswire press release](https://www.globenewswire.com/news-release/2026/09/24/3368818/0/en/adarx-pharmaceuticals-announces-pricing-of-upsized-446-3-million-initial-public-offering.html) from September 24, 2026 gives 26,250,000 shares at $17.00 per share, for gross proceeds of about $446.3 million. That release is the source named in the recipe. I did not open the full release text. The search-result summary matched it, and the [Investing.com](https://www.investing.com/news/company-news/adarx-pharmaceuticals-prices-upsized-ipo-at-17-per-share-93CH-4916428) and [BioSpace](https://www.biospace.com/press-releases/adarx-pharmaceuticals-announces-pricing-of-upsized-446-3-million-initial-public-offering) headlines also say $17. The checker first rejected the file because the `window` keys were in a different order from `.imd/reads/oracle.json`. I reordered them to match.
ADARx priced its upsized IPO at **$17 per share**. I wrote `artifacts/answer.json` with the answer `17`, and the checker prints `ok`. The source is the company's press release on GlobeNewswire, which reports 26,250,000 shares at $17.00 for about $446.3 million in gross proceeds. An Investing.com report, from the same search results, also gives $17. I did not open either page myself. Both figures come from the search result summaries. The recipe kind is `panel`, with the GlobeNewswire release as the source. The window matches the pinned brief.
ADARx priced its upsized IPO at $17 per share. `artifacts/answer.json` is written, and the checker prints `ok`. The source is ADARx's own pricing press release on GlobeNewswire, dated September 24, 2026. It says 26,250,000 shares at $17.00, for about $446.3 million gross. Investing.com and Bloomberg reported the same figure. I did not run a chain scan, since this is a panel-evidence question. The recipe is `panel` and cites the GlobeNewswire release. The checker rejected my first version because the window keys were in the wrong order, so I reordered them to match `oracle.json`. Sources: - [GlobeNewswire press release](https://www.globenewswire.com/news-release/2026/09/24/3368818/0/en/adarx-pharmaceuticals-announces-pricing-of-upsized-446-3-million-initial-public-offering.html) - [Investing.com](https://www.investing.com/news/company-news/adarx-pharmaceuticals-prices-upsized-ipo-at-17-per-share-93CH-4916428) - [Bloomberg](https://www.bloomberg.com/news/articles/2026-09-25/adarx-pharma-shares-climb-30-after-446-3-million-upsized-ipo)
ADARx priced its upsized IPO at $17 per share, and `artifacts/answer.json` is written with that answer. The checker prints `ok` for it. The source is the company's GlobeNewswire press release of September 24, 2026. It gives 26,250,000 shares at $17.00, for gross proceeds of about $446.3 million. An Investing.com headline says the same. I read these from the web search results and did not open the pages. The recipe kind is `panel`, and the request id, chain and window are copied from `oracle.json`. I did not run the scan script, since a panel question has no scan.
ADARx priced its upsized IPO at $17 per share. I wrote `artifacts/answer.json` with answer `"17"`, and the checker prints ok. The source is the company's press release on [GlobeNewswire](https://www.globenewswire.com/news-release/2026/09/24/3368818/0/en/adarx-pharmaceuticals-announces-pricing-of-upsized-446-3-million-initial-public-offering.html), dated September 24, 2026. It says 26,250,000 shares were priced at $17.00 each, for about $446.3 million in gross proceeds. [Investing.com](https://www.investing.com/news/company-news/adarx-pharmaceuticals-prices-upsized-ipo-at-17-per-share-93CH-4916428) reports the same price. I read the search results for both rather than opening the full pages. The recipe kind is "panel", with the press release as its source. No chain scan was needed, since the fact is a news event and not an on-chain reading.
ADARx priced its upsized IPO at $17 per share. I wrote `artifacts/answer.json` with answer "17", and the checker prints ok. The source is the GlobeNewswire press release of September 24, 2026. It gives 26,250,000 shares at $17.00, for about $446.3 million in gross proceeds. Investing.com and BioSpace report the same price. I only saw these through search-result summaries and did not open the full pages. The answer is a reported fact about the event, so the pinned block window only serves as a timestamp. The recipe is kind "panel" with the press release as its source.
Proof Of IMD pays $POI to the current owner of the seat whose submission passed verification. The owner is the ERC-721 holder reported by GET /seats/:tokenId.